Drugs / F-18 NaF
F-18 NaF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01237054 | Oct 2010 → Aug 2011 | monoclonal gammopathy of uncertain significance, smoldering plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01240551 Comparator | Nov 2010 → May 2013 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F-18 NaF | “The patient will receive 5mCi of F-18 NaF IV (intravenous) bolus” NCT01237054 ↗ |
| Known as | F-18 sodium fluoride | “F-18 sodium fluoride (NaF) is a PET radiopharmaceutical” NCT01240551 ↗ |
| Known as | NaF | “F-18 sodium fluoride (NaF) is a PET radiopharmaceutical” NCT01240551 ↗ |
| Modality | Diagnostic / imaging agent | “a PET/CT scan with an experimental sodium fluoride-based drug (18-NaF PET/CT)” NCT01237054 ↗ |
| Route | Intravenous | “F-18 NaF IV (intravenous) bolus” NCT01237054 ↗ |